0001193125-15-391393.txt : 20151201 0001193125-15-391393.hdr.sgml : 20151201 20151201091933 ACCESSION NUMBER: 0001193125-15-391393 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20151201 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20151201 DATE AS OF CHANGE: 20151201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TENET HEALTHCARE CORP CENTRAL INDEX KEY: 0000070318 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 952557091 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07293 FILM NUMBER: 151261341 BUSINESS ADDRESS: STREET 1: 1445 ROSS AVENUE STREET 2: SUITE 1400 CITY: DALLAS STATE: TX ZIP: 75202 BUSINESS PHONE: 469-893-2200 MAIL ADDRESS: STREET 1: 1445 ROSS AVENUE STREET 2: SUITE 1400 CITY: DALLAS STATE: TX ZIP: 75202 FORMER COMPANY: FORMER CONFORMED NAME: NATIONAL MEDICAL ENTERPRISES INC /NV/ DATE OF NAME CHANGE: 19920703 8-K 1 d214937d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report: December 1, 2015

(Date of earliest event reported)

 

 

TENET HEALTHCARE CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

 

Nevada   1-7293   95-2557091

(State

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

1445 Ross Avenue, Suite 1400

Dallas, Texas 75202

(Address of principal executive offices, including zip code)

(469) 893-2200

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 7.01 Regulation FD Disclosure.

On December 1, 2015, Tenet Healthcare Corporation (the “Company”) issued a press release regarding the sale of its Atlanta-area hospitals and related assets. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

 

Item 8.01 Other Events.

On December 1, 2015, a subsidiary of the Company entered into a definitive agreement (the “Asset Sale Agreement”) for the sale of the Company’s five Atlanta-area hospitals and certain related facilities (the “Divested Facilities”) to WellStar Health System, Inc. a non-profit hospital system (“Purchaser”). Subject to the terms and conditions set forth in the Asset Sale Agreement, the Company has agreed to sell the assets of the Divested Facilities to Purchaser for (i) $575 million in cash (subject to customary purchase price adjustments), (ii) the retention of net working capital related to the pre-closing operations of the Divested Facilities (approximately $75 million as of September 30), and (iii) Purchaser’s assumption of the Company’s lease obligations relating to North Fulton Hospital, which assumption is expected to reduce the Company’s total indebtedness by approximately $86 million.

The completion of the transaction is subject to certain closing conditions, including but not limited to (i) certain regulatory or governmental filings and approvals having been made or obtained, (ii) receipt of various third party consents and (iii) Purchaser’s receipt of financing consistent with the terms of the previously delivered commitment letter by a third-party lender (which itself is subject to certain conditions).

The Asset Sale Agreement includes customary representations, warranties, covenants and termination provisions for each of the parties. The Company has also generally agreed to fully indemnify the Purchaser for covered losses arising from liabilities incurred or arising before the closing of the transaction. The parties may terminate the Asset Sale Agreement if the transaction is not consummated on or prior April 30, 2016 (subject to a 90 day extension for regulatory approvals).

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained herein, including in the press release filed as an exhibit to this report, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among others, the following: the future impact of healthcare reform legislation, the enactment of additional federal and state healthcare reform, and the related effect on reimbursement and utilization and the future designs of provider networks and insurance plans, including pricing, provider participation, coverage, co-pays and deductibles; other changes in federal, state and local laws and regulations affecting the healthcare industry; general economic and business conditions, both nationally and regionally; adverse litigation or regulatory developments; the ability to enter into managed care provider arrangements on acceptable terms; cuts to Medicare and Medicaid payment rates or changes in reimbursement practices; trends toward value-based purchasing and alternative payment models; competition; our success in implementing our business development plans; our ability to hire and retain qualified personnel; the availability and terms of capital to fund the expansion of our business, including the acquisition of additional facilities; our success in marketing the revenue cycle management, healthcare information management, management services, and patient communications and engagement services businesses under our Conifer Health Solutions subsidiary; our ability to fully realize the anticipated

 

2


benefits and synergies of our acquisitions and to successfully complete the integration of businesses we acquire, including our United Surgical Partners International joint venture; our ability to identify and execute on measures designed to save or control costs or streamline operations; the impact of our significant indebtedness; our success in operating our health plans and accountable care networks; and our success in completing acquisition and disposition transactions on terms that are favorable to us, including our joint venture transaction with Baylor Scott & White Health in Dallas and the sales of our hospitals in North Carolina and Atlanta, which remain subject to regulatory review and other closing conditions. These and other risks and uncertainties are discussed in the Company’s filings with the Securities and Exchange Commission, including the Company’s annual report on Form 10-K and quarterly reports on Form 10-Q. All information in this report and the press release is as of December 1, 2015. The Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of changes in underlying factors, new information, future events or otherwise.

 

Item 9.01 Financial Statements and Exhibits.

 

  (d) Exhibits

 

  99.1 Press Release issued on December 1, 2015

 

3


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TENET HEALTHCARE CORPORATION
By:   /s/ Daniel J. Cancelmi
  Daniel J. Cancelmi
  Chief Financial Officer

Date: December 1, 2015

 

4


EXHIBIT INDEX

 

99.1 Press Release issued on December 1, 2015

 

5

EX-99.1 2 d214937dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO    LOGO  

Tenet and WellStar Reach Definitive Agreement for

Sale of Tenet’s Atlanta-area Hospitals and Related Operations

DALLAS – December 1, 2015 – Tenet Healthcare Corporation (NYSE:THC) and WellStar Health System have entered into a definitive agreement for the sale and management of Tenet’s five Atlanta-area hospitals. The transaction is subject to customary regulatory approvals and other closing conditions and is expected to be completed as early as the first quarter of 2016.

“We are pleased that our hospitals will join a leading regional healthcare network like WellStar,” said Keith Pitts, vice chairman of Tenet. “This agreement will better position these facilities for long-term success, benefiting all stakeholders.”

The hospitals included in the sale are Atlanta Medical Center and its South Campus, North Fulton Hospital, Spalding Regional Hospital and Sylvan Grove Hospital, as well as 26 physician clinics.

“WellStar plays a pivotal role in the health of our community,” said Candice Saunders, president and chief executive officer of WellStar Health System. “With the addition of Tenet’s metro Atlanta hospitals, we will be better able to provide world-class healthcare to our patients for years to come.”

About Tenet Healthcare

Tenet Healthcare Corporation is a diversified healthcare services company with more than 130,000 employees united around a common mission: to help people live happier, healthier lives. Through its subsidiaries, partnerships and joint ventures, including United Surgical Partners International (USPI), the company operates 87 general acute care hospitals, 20 short-stay surgical hospitals and over 440 outpatient centers in the United States, as well as nine facilities in the United Kingdom. Tenet’s Conifer Health Solutions subsidiary provides technology-enabled performance improvement and health management solutions to hospitals, health systems, integrated delivery networks (IDN), physician groups, self-insured organizations and health plans. For more information, please visit www.tenethealth.com.


The terms “THC”, “Tenet Healthcare Corporation”, “the company”, “we”, “us” or “our” refer to Tenet Healthcare Corporation or one or more of its subsidiaries or affiliates as applicable.

###

 

Corporate Communications

Charles Nicolas

469-893-2640

mediarelations@tenethealth.com

      

 

 

 

Investor Relations

Brendan Strong

469-893-6992

investorrelations@tenethealth.com

  

  

  

  

This release contains “forward-looking statements” – that is, statements that relate to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include, but are not limited to, the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2014, and in our quarterly reports on Form 10-Q, periodic reports on Form 8-K and other filings with the Securities and Exchange Commission. The information contained in this release is as of the date hereof. The company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

Tenet uses its company website to provide important information to investors about the

company including the posting of important announcements regarding financial

performance and corporate developments.

 

Page 2

GRAPHIC 3 g214937g62n50.jpg GRAPHIC begin 644 g214937g62n50.jpg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g214937g69k07.jpg GRAPHIC begin 644 g214937g69k07.jpg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end